Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds?

17 hours ago 3

Faheem Tahir

Sat, June 13, 2026 astatine 12:59 PM CDT 2 min read

With a nett borderline of 34.99% and nett income of $20.64 cardinal (FY25), Eli Lilly and Company (NYSE:LLY) ranks among the most profitable bluish spot stocks to bargain according to hedge funds. Meanwhile, analysts spot 9.20% upside for the stock. That outlook comes during a peculiarly progressive agelong of regulatory and objective quality for Lilly's cause pipeline.

Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds?

Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds?

On June 9, 2026, the FDA approved a caller attraction dosing regimen for EBGLYSS (lebrikizumab-lbkz), allowing a azygous 250 mg injection each 8 weeks for adults and children 12 and older weighing astatine slightest 88 pounds with moderate-to-severe atopic dermatitis. EBGLYSS was already approved for once-monthly attraction dosing, and the caller enactment gives patients arsenic fewer arsenic six attraction injections per year.

That update followed a question of diabetes and obesity information presented astatine the ADA 86th Scientific Sessions.

On June 8, 2026, Eli Lilly and Company (NYSE:LLY) reported that Foundayo (orforglipron) outperformed oral semaglutide connected A1C simplification and value nonaccomplishment successful the ACHIEVE-3 trial, with akin gains shown successful ACHIEVE-2 and ACHIEVE-5. A time earlier, Lilly said Foundayo produced important value nonaccomplishment crossed each stages of menopause successful post-hoc analyses of the ATTAIN-1 and ATTAIN-2 trials. Additionally, connected June 6, 2026, Eli Lilly and Company (NYSE:LLY) reported afloat information from retatrutide's TRIUMPH-1 obesity survey and TRANSCEND-T2D-1 survey successful benignant 2 diabetes, showing important value nonaccomplishment alongside improvements successful genu osteoarthritis pain, slumber apnea, and A1C levels.

Following those updates, Jefferies raised its terms people connected Eli Lilly and Company (NYSE:LLY) to $1,350 from $1,330 and kept a "Buy" rating. The steadfast said immoderate information observations were manageable and that retatrutide's wide illustration would beryllium hard to bushed successful a modern large-scale planetary obesity Phase 3 trial.

Eli Lilly and Company (NYSE:LLY) is simply a healthcare institution that develops quality pharmaceutical products crossed cardiometabolic health, oncology, and immunology.

While we admit the imaginable of LLY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article